BRMS1 antibody (N-Term)
Quick Overview for BRMS1 antibody (N-Term) (ABIN6256973)
Target
See all BRMS1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Specificity
- BRMS1 Antibody detects endogenous levels of total BRMS1.
-
Predicted Reactivity
- Pig,Horse,Sheep,Dog
-
Purification
- The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
-
Immunogen
- A synthesized peptide derived from human BRMS1, corresponding to a region within N-terminal amino acids.
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB 1:500-1:1000, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C. Stable for 12 months from date of receipt.
-
Expiry Date
- 12 months
-
-
- BRMS1 (Breast Cancer Metastasis Suppressor 1 (BRMS1))
-
Alternative Name
- BRMS1
-
Background
-
Description: Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.
Gene: BRMS1
-
Molecular Weight
- 28 kDa
-
Gene ID
- 25855
-
UniProt
- Q9HCU9
Target
-